Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Journal: Blood
Publication Year: 2015
Authors: Markus Muschen
PubMed link: 25878119
Funding Grants: Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication

Public Summary:
Inhibitors of B-cell receptor (BCR) and pre-BCR signaling were successfully introduced into patient care for various subtypes of mature B-cell lymphoma (e.g., ibrutinib, idelalisib). Acute lymphoblastic leukemia (ALL) typically originates from pre-B cells that critically depend on survival signals emanating from a functional pre-BCR. However, whether patients with ALL benefit from treatment with pre-BCR inhibitors has not been explored. Recent data suggest that the pre-BCR functions as tumor suppressor in the majority of cases of human ALL. However, a distinct subset of human ALL is selectively sensitive to pre-BCR antagonists.

Scientific Abstract:
Inhibitors of B-cell receptor (BCR) and pre-BCR signaling were successfully introduced into patient care for various subtypes of mature B-cell lymphoma (e.g., ibrutinib, idelalisib). Acute lymphoblastic leukemia (ALL) typically originates from pre-B cells that critically depend on survival signals emanating from a functional pre-BCR. However, whether patients with ALL benefit from treatment with pre-BCR inhibitors has not been explored. Recent data suggest that the pre-BCR functions as tumor suppressor in the majority of cases of human ALL. However, a distinct subset of human ALL is selectively sensitive to pre-BCR antagonists.

Source URL: https://www.cirm.ca.gov/about-cirm/publications/rationale-targeting-pre-b-cell-receptor-signaling-pathway-acute